Barriers and opportunities in pancreatic cancer immunotherapy

IF 6.8 1区医学 Q1 ONCOLOGY

NPJ Precision Oncology Pub Date : 2024-09-12 DOI:10.1038/s41698-024-00681-z

Yixin Ju, Dongzhi Xu, Miao-miao Liao, Yutong Sun, Wen-dai Bao, Fan Yao, Li Ma

{"title":"Barriers and opportunities in pancreatic cancer immunotherapy","authors":"Yixin Ju, Dongzhi Xu, Miao-miao Liao, Yutong Sun, Wen-dai Bao, Fan Yao, Li Ma","doi":"10.1038/s41698-024-00681-z","DOIUrl":null,"url":null,"abstract":"Pancreatic ductal adenocarcinoma (PDAC) presents a fatal clinical challenge characterized by a dismal 5-year overall survival rate, primarily due to the lack of early diagnosis and limited therapeutic efficacy. Immunotherapy, a proven success in multiple cancers, has yet to demonstrate significant benefits in PDAC. Recent studies have revealed the immunosuppressive characteristics of the PDAC tumor microenvironment (TME), including immune cells with suppressive properties, desmoplastic stroma, microbiome influences, and PDAC-specific signaling pathways. In this article, we review recent advances in understanding the immunosuppressive TME of PDAC, TME differences among various mouse models of pancreatic cancer, and the mechanisms underlying resistance to immunotherapeutic interventions. Furthermore, we discuss the potential of targeting cancer cell-intrinsic pathways and TME components to sensitize PDAC to immune therapies, providing insights into strategies and future perspectives to break through the barriers in improving pancreatic cancer treatment.","PeriodicalId":19433,"journal":{"name":"NPJ Precision Oncology","volume":null,"pages":null},"PeriodicalIF":6.8000,"publicationDate":"2024-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.nature.com/articles/s41698-024-00681-z.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"NPJ Precision Oncology","FirstCategoryId":"3","ListUrlMain":"https://www.nature.com/articles/s41698-024-00681-z","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Pancreatic ductal adenocarcinoma (PDAC) presents a fatal clinical challenge characterized by a dismal 5-year overall survival rate, primarily due to the lack of early diagnosis and limited therapeutic efficacy. Immunotherapy, a proven success in multiple cancers, has yet to demonstrate significant benefits in PDAC. Recent studies have revealed the immunosuppressive characteristics of the PDAC tumor microenvironment (TME), including immune cells with suppressive properties, desmoplastic stroma, microbiome influences, and PDAC-specific signaling pathways. In this article, we review recent advances in understanding the immunosuppressive TME of PDAC, TME differences among various mouse models of pancreatic cancer, and the mechanisms underlying resistance to immunotherapeutic interventions. Furthermore, we discuss the potential of targeting cancer cell-intrinsic pathways and TME components to sensitize PDAC to immune therapies, providing insights into strategies and future perspectives to break through the barriers in improving pancreatic cancer treatment.

Abstract Image

查看原文本刊更多论文

胰腺癌免疫疗法的障碍与机遇

胰腺导管腺癌（PDAC）是一项致命的临床挑战，其特点是 5 年总生存率令人沮丧，这主要是由于缺乏早期诊断和治疗效果有限。免疫疗法在多种癌症中取得了成功，但在 PDAC 中尚未显示出显著疗效。最近的研究揭示了 PDAC 肿瘤微环境（TME）的免疫抑制特性，包括具有抑制特性的免疫细胞、脱瘤基质、微生物组影响和 PDAC 特异性信号通路。在本文中，我们回顾了在了解 PDAC 的免疫抑制性 TME、各种胰腺癌小鼠模型的 TME 差异以及免疫治疗干预耐药机制方面的最新进展。此外，我们还讨论了以癌细胞内在通路和TME成分为靶点使PDAC对免疫疗法敏感的可能性，为突破胰腺癌治疗障碍的策略和未来前景提供了见解。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

NPJ Precision Oncology ONCOLOGY-

CiteScore

9.90

自引率

1.30%

发文量

审稿时长

18 weeks

期刊介绍： Online-only and open access, npj Precision Oncology is an international, peer-reviewed journal dedicated to showcasing cutting-edge scientific research in all facets of precision oncology, spanning from fundamental science to translational applications and clinical medicine.